Advanced Enzyme Q4 Review - Outlook Remains Challenging In Medium Term: ICICI Direct

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..ICICI Direct Report.Advanced Enzyme Technologies Ltd.'s revenues declined 1% YoY to Rs 132 crore on the back of 7% YoY de-growth in human nutrition segment to Rs 86 crore being partially offset by growth of 16% YoY in animal nutrition to Rs 15 crore. Bio processing segment de-grew 5% YoY to Rs 19 crore while specialised manufacturing sales was at Rs 11 crore this quarter. Ebitda margins contracted 1060 bps YoY to 31% mainly due to higher other expenditure. Subsequently, Ebitda de-grew 27% YoY to Rs 40 crore while net profit declined 23% YoY to Rs 24 crore.Advanced Enzyme reported below par performance this quarter and margins was significantly below our estimates..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Advanced Enzyme Q4 Review - Outlook Remains Challenging In Medium Term: ICICI Direct

Advanced Enzyme Q4 Review - Outlook Remains Challenging In Medium Term: ICICI Direct

Choose a plan